Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease

Journal of Heart and Lung Transplantation

Volumn 23, Issue 1, 2004, Pages 80-87

  Goetze, Jens Peter ^a   Videbaek, Regitze ^a   Boesgaard, Soren ^a   Aldershvile, Jan ^a   Rehfeld, Jens F ^a   Carlsen, Jorn ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC MONITORING; HUMAN; HUMAN TISSUE; LUNG DISEASE; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; TERMINALLY ILL PATIENT;

EID: 0347004467     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(03)00060-3     Document Type: Article

References (36)

1. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 339:1998;321-328.
2. Cowie M.R., Struthers A.D., Wood D.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
3. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 351:1998;9-13.
4. Muders F., Kromer E.P., Griese D.P., et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J. 134:1997;442-449.
5. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:2001;1014-1021.
6. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide . Circulation. 105:2002;1760-1763.
7. Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 214:1995;1175-1183.
8. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction . Circulation. 97:1998;1921-1929.
9. Talwar S., Squire I.B., Downie P.F., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J. 21:2000;1514-1521.
10. de Bold A.J., Ma K.K., Zhang Y., de Bold M.L., Bensimon M., Khoshbaten A. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol. 79:2001;705-714.
11. Doyama K., Fukumoto M., Takemura G., et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 32:1998;1832-1838.
12. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension relation to hemodynamic variables and endothelin levels . J Am Coll Cardiol. 26:1995;1581-1585.
13. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 31:1998;202-208.
14. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 102:2000;865-870.
15. Matsuo K., Nishikimi T., Yutani C., et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation. 98:1998;2433-2440.
16. Ishii J., Nomura M., Ito M., et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 301:2000;19-30.
17. Tulevski I.I., Groenink M., Der Wall E.E., et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload correlation between plasma neurohormones and right ventricular dysfunction . Heart. 86:2001;27-30.
18. Tulevski I.I., Hirsch A., Sanson B.J., et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost. 86:2001;1193-1196.
19. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 106:2002;92-99.
20. Nagaya N., Ando M., Oya H., et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg. 74:2002;180-184.
21. Tulevski I.I., Mulder B.J., van Veldhuisen D.J. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 39:2002;2080.
22. Davis M., Espiner E., Richards G., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
23. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 37:2001;379-385.
24. Cabanes L., Richaud-Thiriez B., Fulla Y., et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 120:2001;2047-2050.
25. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med. 39:2002;131-138.
26. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 39:2002;202-209.
27. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 347:2002;161-167.
28. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension A national prospective study . Ann Intern Med. 107:1987;216-223.
29. Kettunen R.V., Leppaluoto J., Jounela A., Vuolteenaho O. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J. 127:1994;1449-1455.
30. Goetze J.P., Kastrup J., Pedersen F., Rehfeld J.F. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem. 48:2002;1035-1042.
31. Gotze J.P., Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. Scand J Clin Lab Invest. 234:(Suppl):2001;47-51.
32. Edwards B.S., Zimmerman R.S., Schwab T.R., Heublein D.M., Burnett J.C. Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 62:1988;191-195.
33. Christoffersen C., Goetze J.P., Bartels E.D., et al. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension. 40:2002;54-60.
34. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J. 142:2001;725-732.
35. Adachi S., Ito H., Ohta Y., et al. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol. 268:1995;H162-H169.
36. Li C., Booze R.M., Hersh L.B. Tissue-specific expression of rat neutral endopeptidase (neprilysin) mRNAs. J Biol Chem. 270:1995;5723-5728.